Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | BRS3 | P32247 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22994484 | 0.89 | BRS3 (0.50) | CYP11B1CYP11B2CYP3A4NPC1RAB9A | |
| SCHEMBL18790846 | 0.88 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP3A4NPC1RAB9A | |
| SCHEMBL25137959 | 0.86 | CYP11B1 (0.54) | CYP11B1CYP11B2CYP3A4NPC1RAB9A | |
| SCHEMBL22994398 | 0.84 | AURKA (0.51) | CYP11B1CYP11B2CYP3A4NPC1RAB9A | |
| SCHEMBL30320110 | 0.84 | AURKA (0.51) | CYP11B1CYP11B2CYP3A4NPC1RAB9A | |
| SCHEMBL28583022 | 0.82 | CYP11B1 (0.55) | CYP11B1CYP11B2CYP3A4NPC1RAB9A | |
| SCHEMBL18790955 | 0.81 | CYP11B1 (0.47) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL20781811 | 0.80 | CYP11B1 (0.50) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20122190 | 0.79 | CYP11B1 (0.80) | CYP11B1CYP11B2CYP3A4NPC1RAB9A | |
| SCHEMBL146559 | 0.79 | NPC1 (0.65) | CYP11B1CYP11B2CYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040512-A | Organic electroluminescent material and device thereof | 北京夏禾科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119823187-A | Organic electroluminescent material and device thereof | 北京夏禾科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-114907413-B | Organic electroluminescent material and device thereof | 北京夏禾科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114907412-B | Organic electroluminescent material and device thereof | 北京夏禾科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12022727-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240025934-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-11844267-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-12-12 | — | — | US | disclosed |
| US-11839142-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-12-05 | — | — | US | disclosed |
| US-11825734-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230365607-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-16 | — | — | US | disclosed |
| US-11139443-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10844084-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200144520-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2020-05-07 | — | — | US | disclosed |
| US-20190252627-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190135841-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20180175308-A1 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2018-06-21 | — | — | US | disclosed |
| EP-3159350-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3001480-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2017-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844267-B2 | Organic electroluminescent materials and devices | L1CAM, LEF1, EPCAM | CYP11B1 3419/4885CYP11B2 2511/4885CYP3A4 2027/4885 |
| US-20240025934-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | SSB, RO60, LIFR | CYP11B1 3789/4885CYP11B2 3994/4885CYP3A4 3160/4885 |
| US-20200144520-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, OSBP | CYP11B1 1965/4885CYP11B2 1677/4885CYP3A4 523/4885 |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CYP11B1 368/4885CYP11B2 295/4885CYP3A4 3142/4885 |
| US-11825734-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OSBP | CYP11B1 1965/4885CYP11B2 1677/4885CYP3A4 523/4885 |
| US-20180175308-A1 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, OSBP | CYP11B1 364/4885CYP11B2 489/4885CYP3A4 334/4885 |
| US-20190252627-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | L1CAM, LEF1, EPCAM | CYP11B1 1174/4885CYP11B2 1216/4885CYP3A4 784/4885 |
| US-20230365607-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, OR10J3 | CYP11B1 1221/4885CYP11B2 1004/4885CYP3A4 1083/4885 |
| US-11139443-B2 | Organic electroluminescent materials and devices | ICOSLG, ORC3, OR10J3 | CYP11B1 2255/4885CYP11B2 1775/4885CYP3A4 2415/4885 |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CYP11B1 368/4885CYP11B2 295/4885CYP3A4 3142/4885 |
| US-12022727-B2 | Organic electroluminescent materials and devices | OCIAD1, OSBP, OCIAD2 | CYP11B1 409/4885CYP11B2 570/4885CYP3A4 1418/4885 |
| US-20190135841-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, YBX3 | CYP11B1 1039/4885CYP11B2 958/4885CYP3A4 1527/4885 |
| US-10844084-B2 | Organic electroluminescent materials and devices | L1CAM, EPCAM, OR10J3 | CYP11B1 2755/4885CYP11B2 2038/4885CYP3A4 724/4885 |
| US-11839142-B2 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, OSBP | CYP11B1 420/4885CYP11B2 444/4885CYP3A4 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.